ePrints

Current and emerging therapies for Addison's disease

Lookup NU author(s): Dr Catherine Napier, Professor Simon PearceORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Purpose of reviewThe purpose of this article is to review the current therapy of Addison's disease and to highlight recent developments in this field.Recent findingsConventional steroid replacement for Addison's disease consists of twice or three-times daily oral hydrocortisone and once-daily fludrocortisone; however, new treatment modalities such as modified-released hydrocortisone and continuous subcutaneous hydrocortisone infusion have recently been developed. These offer the potential for closer simulation of the physiological serum cortisol rhythm. Two studies have also looked at modifying the natural history of adrenal failure using adrenocorticotropic hormone (ACTH) stimulation and immunomodulatory therapies, leading to the concept of residual adrenal function in some Addison's disease patients.SummaryFollowing more than 60 years with no significant innovation in the management of Addison's disease, these new approaches hold promise for improved patient health and better quality of life in the future.

Publication metadata

Author(s): Napier C, Pearce SHS

Publication type: Review

Publication status: Published

Journal: Current Opinion in Endocrinology, Diabetes & Obesity

Year: 2014

Volume: 21

Issue: 3

Pages: 147-153

Print publication date: 01/06/2014

ISSN (print): 1752-296X

ISSN (electronic): 1752-2978

Publisher: LIPPINCOTT WILLIAMS & WILKINS

URL: http://dx.doi.org/10.1097/MED.0000000000000067

DOI: 10.1097/MED.0000000000000067

Share